159837 生物科技
已收盘 11-12 15:00:00
资讯
新帖
简况
腾盛博药生物科技02137.HK回购14.35万股并因股份奖励归属发行5875股
同花顺 · 11-12 20:47
腾盛博药生物科技02137.HK回购14.35万股并因股份奖励归属发行5875股
美股生物科技内部人交易分化：ImmunityBio(IBRX.US)套现最多，Sellas(SLS.US)董事在5倍大涨前买入
同花顺 · 11-12 16:30
美股生物科技内部人交易分化：ImmunityBio(IBRX.US)套现最多，Sellas(SLS.US)董事在5倍大涨前买入
ETF收评|科创50指数涨0.73%，QDIIETF午后拉升，标普油气ETF涨3%，纳指生物科技ETF涨2%
格隆汇 · 11-12 15:37
ETF收评|科创50指数涨0.73%，QDIIETF午后拉升，标普油气ETF涨3%，纳指生物科技ETF涨2%
腾盛博药生物科技于联交所回购4.2万股 涉资4.4025万港元
同花顺 · 11-11 20:15
腾盛博药生物科技于联交所回购4.2万股 涉资4.4025万港元
腾盛博药生物科技回购43万股并因购股权行使发行1.2万股
同花顺 · 11-10 19:23
腾盛博药生物科技回购43万股并因购股权行使发行1.2万股
生物科技IPO热潮延续！Windward Bio(WWB.US)拟募资1.85亿美元，押注半年给药一次的抗体药物
智通财经 · 11-09
生物科技IPO热潮延续！Windward Bio(WWB.US)拟募资1.85亿美元，押注半年给药一次的抗体药物
腾盛博药生物科技回购35.9万股 涉资约37.15万港元
同花顺 · 11-06
腾盛博药生物科技回购35.9万股 涉资约37.15万港元
葛兰素史克站台：抗炎生物科技公司Rezera(RZRA.US)拟通过IPO募资2亿美元，估值2.54亿美元
智通财经 · 11-06
葛兰素史克站台：抗炎生物科技公司Rezera(RZRA.US)拟通过IPO募资2亿美元，估值2.54亿美元
花旗：中国制药及生物科技ESMO数据再获验证 医药首选石药集团及恒瑞医药
同花顺 · 11-03
花旗：中国制药及生物科技ESMO数据再获验证 医药首选石药集团及恒瑞医药
花旗：中国制药及生物科技ESMO数据再获验证 看好石药、恒瑞、信达生物及科伦博泰
同花顺 · 11-02
花旗：中国制药及生物科技ESMO数据再获验证 看好石药、恒瑞、信达生物及科伦博泰
Anthropic 收购单人生物科技公司 Mithril Medicine，启动自有药物研发项目
链捕手 · 10-28
Anthropic 收购单人生物科技公司 Mithril Medicine，启动自有药物研发项目
打破部门壁垒的生物科技领军人物
环球市场播报 · 10-28
打破部门壁垒的生物科技领军人物
免疫学与炎症生物科技公司Bambusa(BBTX.US)IPO定价15-17美元/股 拟筹资1.5亿美元
同花顺 · 10-27
免疫学与炎症生物科技公司Bambusa(BBTX.US)IPO定价15-17美元/股 拟筹资1.5亿美元
腾盛博药生物科技回购11万股并因股份奖励归属发行132,700股新股
同花顺 · 10-27
腾盛博药生物科技回购11万股并因股份奖励归属发行132,700股新股
A股三大指数早盘震荡走低 深成指半日跌0.33% 航天军工、生物科技等板块跌幅居前
金吾财讯 · 10-27
A股三大指数早盘震荡走低 深成指半日跌0.33% 航天军工、生物科技等板块跌幅居前
生物科技公司Lycia Therapeutics(LYCA.US)登陆美股市场 股价涨超32%
同花顺 · 10-24
生物科技公司Lycia Therapeutics(LYCA.US)登陆美股市场 股价涨超32%
美股异动 | 生物科技公司Lycia Therapeutics(LYCA.US)登陆美股市场 股价涨超32%
智通财经 · 10-24
美股异动 | 生物科技公司Lycia Therapeutics(LYCA.US)登陆美股市场 股价涨超32%
腾盛博药生物科技于香港联交所回购1.6万股 每股作价0.905港元
同花顺 · 10-21
腾盛博药生物科技于香港联交所回购1.6万股 每股作价0.905港元
OpenAI宣布收购AI生物科技初创企业Orchestra Bio
IT之家 · 10-21
OpenAI宣布收购AI生物科技初创企业Orchestra Bio
腾盛博药生物科技回购3万股 涉资约2.67万港元
同花顺 · 10-20
腾盛博药生物科技回购3万股 涉资约2.67万港元
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159837","market":"SZ","secType":"STK","nameCN":"生物科技","latestPrice":0.485,"timestamp":1794467016000,"preClose":0.487,"halted":0,"volume":43763000,"delay":0,"changeRate":-0.0041,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.002,"latestTime":"11-12 15:00:00","open":0.487,"high":0.49,"low":0.479,"amount":21219300,"amplitude":0.0226,"askPrice":0.485,"askSize":4449,"bidPrice":0.484,"bidSize":978,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794533400000},"marketStatusCode":5,"adr":0,"adjPreClose":0.487,"symbolType":"fund","openAndCloseTimeList":[[1794447000000,1794454200000],[1794459600000,1794466800000]],"highLimit":0.536,"lowLimit":0.438,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":-0.040406,"marketValue":0,"turnoverRate":0,"status":1,"floatMarketCap":0},"requestUrl":"/m/hq/s/159837","defaultTab":"news","newsList":[{"id":"2682359663","title":"腾盛博药生物科技02137.HK回购14.35万股并因股份奖励归属发行5875股","url":"https://stock-news.laohu8.com/highlight/detail?id=2682359663","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682359663?lang=zh_cn&edition=full","pubTime":"2026-11-12 20:47","pubTimestamp":1794487620,"startTime":"0","endTime":"0","summary":"11月12日，腾盛博药-B(02137.HK)在香港联交所回购143,500股普通股，每股价格区间为HKD1.025至HKD1.055，付出总额HKD149,667.5，回购股份持作库存股份。同日，公司因2023年股份奖励计划授出 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261112/c681770371.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261112/c681770371.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682556388","title":"美股生物科技内部人交易分化：ImmunityBio(IBRX.US)套现最多，Sellas(SLS.US)董事在5倍大涨前买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2682556388","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682556388?lang=zh_cn&edition=full","pubTime":"2026-11-12 16:30","pubTimestamp":1794472200,"startTime":"0","endTime":"0","summary":"在生物科技板块，药物研发进展固然是股价的核心变量，但公司内部人的买卖动向同样是观察公司前景的重要因素。从这个角度看，Capricor(CAPR.US)、ImmunityBio(IBRX.US)、Sellas(SLS.US)和Iov ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/usstock/20261112/c681755625.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/usstock/20261112/c681755625.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682575275","title":"ETF收评|科创50指数涨0.73%，QDIIETF午后拉升，标普油气ETF涨3%，纳指生物科技ETF涨2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2682575275","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682575275?lang=zh_cn&edition=full","pubTime":"2026-11-12 15:37","pubTimestamp":1794469039,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["159837","159697","159371","159659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682301480","title":"腾盛博药生物科技于联交所回购4.2万股 涉资4.4025万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682301480","media":"同花顺","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682301480?lang=zh_cn&edition=full","pubTime":"2026-11-11 20:15","pubTimestamp":1794399300,"startTime":"0","endTime":"0","summary":"11月11日，腾盛博药-B(02137.HK)在香港联合交易所回购42,000股普通股，每股最高购回价HKD1.055，最低购回价HKD1.045，付出的价格总额为HKD44,025。回购股份被持作库存股份，拟注销数目为0。 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261111/c681719619.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261111/c681719619.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682391356","title":"腾盛博药生物科技回购43万股并因购股权行使发行1.2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2682391356","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682391356?lang=zh_cn&edition=full","pubTime":"2026-11-10 19:23","pubTimestamp":1794309780,"startTime":"0","endTime":"0","summary":"11月10日，腾盛博药-B(02137.HK)在香港联交所回购430,000股普通股，每股价格区间为HKD1.01至HKD1.05，付出价格总额为HKD444,312.5，回购股份持作库存股份。同日，公司因雇员行使2023年9月1 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261110/c681671589.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261110/c681671589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682385285","title":"生物科技IPO热潮延续！Windward Bio(WWB.US)拟募资1.85亿美元，押注半年给药一次的抗体药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2682385285","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682385285?lang=zh_cn&edition=full","pubTime":"2026-11-09 21:21","pubTimestamp":1794230461,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞士临床阶段生物科技公司Windward Bio Group计划在美国首次公开募股中寻求最高10亿美元的估值。在市场环境动荡、借贷成本上升拖累其他行业的IPO活动之际，生物科技企业IPO已成为今年秋季美股IPO市场的重要支柱。除了Windward Bio之外，药物开发商Rezera上周也启动了美国IPO路演，预计将于本周在纽约上市。资料显示，Windward Bio正在开发用于治疗哮喘、慢性阻塞性肺病和特应性皮炎的超长效抗体药物，旨在减少给药频率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1520701.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AGNG","IPOS","MEDX","LNGR","159837","BK4588","XBI","FRHC","SYNB","IBBJ","BK4581","HBImain","REDS","BK4127","KCE","BK4585","IEIH","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681861788","title":"腾盛博药生物科技回购35.9万股 涉资约37.15万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681861788","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681861788?lang=zh_cn&edition=full","pubTime":"2026-11-06 21:19","pubTimestamp":1793971140,"startTime":"0","endTime":"0","summary":"11月6日，腾盛博药-B(02137.HK)于香港联交所回购35.9万股普通股，每股回购价最高HKD1.05、最低HKD1.015，合共付出HKD371,547.5。回购股份持作库存股份，拟注销数目为0。回购后，已发行股份( ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261106/c681570916.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261106/c681570916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681858369","title":"葛兰素史克站台：抗炎生物科技公司Rezera(RZRA.US)拟通过IPO募资2亿美元，估值2.54亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681858369","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681858369?lang=zh_cn&edition=full","pubTime":"2026-11-06 15:40","pubTimestamp":1793950835,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Rezera是一家即将进入三期临床、开发用于炎症性疾病的口服NLRP3抑制剂的生物科技公司，该公司周四公布了其IPO条款。新投资者及关联方葛兰素史克已表示有意认购此次IPO中至多2500万美元的份额。按拟议区间的中值计算，Rezera的完全稀释市值将达2.54亿美元。Rezera正在开发口服NLRP3抑制剂，用于心血管和神经炎症疾病。公司保留所有候选药物的全球权益。Rezera成立于2016年，计划以股票代码“RZRA”在纳斯达克上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1519590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCE","REDS","BK4127","IPOS","SYNB","BK4585","XBI","AGNG","BK4588","MEDX","IBBJ","GDOC","BK4581","HBImain","LNGR","RZRA","IEIH","159837","FRHC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680790285","title":"花旗：中国制药及生物科技ESMO数据再获验证 医药首选石药集团及恒瑞医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2680790285","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680790285?lang=zh_cn&edition=full","pubTime":"2026-11-03 09:38","pubTimestamp":1793669880,"startTime":"0","endTime":"0","summary":"花旗发布研报称，ESMO2026标志着中国制药及生物科技又迈出重要一步，中国原研资产于多项全球关键研究交出具说服力数据，并展现强劲的中国至全球一致性、高关注度临床结果，以及超越既有靶点 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261103/c681387507.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261103/c681387507.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0188","LU2495084118.USD","LU2097828631.EUR","159938","BK0239","BK0028","LU2488822045.USD","LU2580892862.HKD","LU1255011170.USD","BK0183","LU0405327494.USD","LU1328615791.USD","LU1064130708.USD","LU2097828714.EUR","LU2097828474.EUR","LU2580892789.USD","LU1969619763.USD","LU1997244956.HKD","LU1146622755.USD","LU2097828557.USD","LU1580142542.USD","LU1781817850.SGD","LU1820825898.SGD","BK0012","BK0060","LU1655091616.SGD","600276","LU1997245094.SGD","LU2097828805.USD","LU2328871848.SGD","LU1064131003.USD","159837","LU0405327148.USD","LU1997245177.USD","LU2148510915.USD","LU2289578879.USD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680875430","title":"花旗：中国制药及生物科技ESMO数据再获验证 看好石药、恒瑞、信达生物及科伦博泰","url":"https://stock-news.laohu8.com/highlight/detail?id=2680875430","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680875430?lang=zh_cn&edition=full","pubTime":"2026-11-02 20:02","pubTimestamp":1793620920,"startTime":"0","endTime":"0","summary":"11月2日，花旗发表研究报告指，ESMO2026标志着中国制药及生物科技又迈出了重要一步，中国原研资产于多项全球关键研究交出具说服力数据，并展现强劲的中国至全球一致性、高关注度临床结果， ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261102/c681371096.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261102/c681371096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678046081","title":"Anthropic 收购单人生物科技公司 Mithril Medicine，启动自有药物研发项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2678046081","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678046081?lang=zh_cn&edition=full","pubTime":"2026-10-28 19:56","pubTimestamp":1793188604,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据 TNW 报道，Anthropic 在周二的博客文章中宣布收购 Mithril Medicine。\n\n这家公司只有一名员工，研发两种罕见肌营养不良症的疗法。交易条款未披露，创始人 Cody Tranbarger 已加入 Anthropic。 ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2299613","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","159837","BK4588","MEDX","XBI","ANT","IBBJ","BK4585","IEIH","LNGR","BK4581","SYNB","HBImain","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678101014","title":"打破部门壁垒的生物科技领军人物","url":"https://stock-news.laohu8.com/highlight/detail?id=2678101014","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678101014?lang=zh_cn&edition=full","pubTime":"2026-10-28 00:22","pubTimestamp":1793118120,"startTime":"0","endTime":"0","summary":"杰夫莱登在生物科技行业拥有一段堪称传奇的经历。如今他担任执行董事长，Vertex 的股价已经飙升至 500 美元以上。莱登表示，上任第一年他把精力放在制定战略上。生物科技与制药企业面临一个现实：进入临床试验的药物，失败率超过 90%。为此莱登制定一套战略：只研究经过验证的疾病靶点。莱登选择了截然不同的方式。莱登强调，搭建这套文化，招对人至关重要，新员工入职引导与培训同样不可或缺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-10-28/doc-iniwswns0135775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IEIH","BK4585","SYNB","IBBJ","159837","MEDX","AGNG","XBI","GDOC","LNGR","BK4588","HBImain","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678123173","title":"免疫学与炎症生物科技公司Bambusa(BBTX.US)IPO定价15-17美元/股 拟筹资1.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678123173","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678123173?lang=zh_cn&edition=full","pubTime":"2026-10-27 15:13","pubTimestamp":1793085180,"startTime":"0","endTime":"0","summary":"专注于免疫学和炎症领域的生物科技公司Bambusa Therapeutics周一公布了其首次公开募股(IPO)的发行条款。该公司计划通过发行940万股股票，以每股15至17美元的价格区间筹集1.5亿美元。按照拟 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/usstock/20261027/c681130478.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/usstock/20261027/c681130478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678142151","title":"腾盛博药生物科技回购11万股并因股份奖励归属发行132,700股新股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678142151","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678142151?lang=zh_cn&edition=full","pubTime":"2026-10-27 13:12","pubTimestamp":1793077920,"startTime":"0","endTime":"0","summary":"腾盛博药-B(02137.HK)于2026年10月26日于香港联交所回购110,000股普通股，每股价格区间为HKD0.9至HKD0.935，总额HKD100,922.5，回购股份持作库存股份。同日，公司因2023年股份奖励计划项下 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261027/c681126653.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261027/c681126653.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678198141","title":"A股三大指数早盘震荡走低 深成指半日跌0.33% 航天军工、生物科技等板块跌幅居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2678198141","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678198141?lang=zh_cn&edition=full","pubTime":"2026-10-27 11:35","pubTimestamp":1793072158,"startTime":"0","endTime":"0","summary":"金吾财讯 | A股三大指数早盘震荡走低，截至午间收盘，沪指跌0.13%，深成指跌0.33%，创业板指跌0.45%。盘面上看，航天军工、生物科技、软件等板块跌幅居前；海运、银行、贵金属等板块涨幅居前。华西证券表示，当前点位上，投资者不应悲观，预计A股大概率在蓄势中触底反弹。当前A股不宜过度悲观，市场正处于蓄势筑底阶段，触底反弹可期。基金仓位、市场情绪等指标回落至底部区间，抛压逐步衰竭。政策托底持续加码，等待数据验证；盈利呈结构性修复，外部美债进一步大幅收紧概率下降，外部冲击转为扰动；ETF、险资等长线资金逆势布局，为底部提供承接，行情主要矛盾转为等待催化、信心修复。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/NzMyOTI2MTc2NzYxOTM1NTM3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NzMyOTI2MTc2NzYxOTM1NTM3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994538","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["82846","03188","02843","02827","83130","BK4585","IEIH","GDOC","03130","159982","XBI","02823","02846","SYNB","82823","BK1147","SHLD","161024","AGNG","82822","MEDX","LNGR","02822","399300","399001","BK4581","BK1610","159837","BK4588","IBBJ","HBImain","82843","07233","83188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677979668","title":"生物科技公司Lycia Therapeutics(LYCA.US)登陆美股市场 股价涨超32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677979668","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677979668?lang=zh_cn&edition=full","pubTime":"2026-10-24 00:35","pubTimestamp":1792773300,"startTime":"0","endTime":"0","summary":"周五，专注于过敏和自身免疫性疾病治疗的生物科技公司Lycia Therapeutics(LYCA.US)登陆美股市场，开盘后股价涨超32%，报23.9美元。IPO价格为18美元。Lycia Therapeutics致力于开发旨在降解 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/usstock/20261024/c681046207.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/usstock/20261024/c681046207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677979350","title":"美股异动 | 生物科技公司Lycia Therapeutics(LYCA.US)登陆美股市场 股价涨超32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677979350","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677979350?lang=zh_cn&edition=full","pubTime":"2026-10-24 00:27","pubTimestamp":1792772851,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，专注于过敏和自身免疫性疾病治疗的生物科技公司Lycia Therapeutics(LYCA.US)登陆美股市场，开盘后股价涨超32%，报23.9美元。IPO价格为18美元。Lycia Therapeutics致力于开发旨在降解致病细胞外蛋白的疗法，初期聚焦自身免疫、炎症和过敏性疾病。其技术平台名为LYTAC(溶酶体靶向嵌合体)，基于诺贝尔奖得主Carolyn Bertozzi在斯坦福大学的研究工作。其主要候选药物LCA-0061旨在降解免疫球蛋白E(IgE)，用于治疗包括食物过敏在内的过敏性疾病，目前处于一期临床试验阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1511943.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","GDOC","SYNB","LENZ","BK4139","IEIH","IBBJ","LNGR","LYCA","XBI","BK4539","BK4007","BK4585","AGNG","MEDX","BK4581","HBImain","159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677674519","title":"腾盛博药生物科技于香港联交所回购1.6万股 每股作价0.905港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677674519","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677674519?lang=zh_cn&edition=full","pubTime":"2026-10-21 20:47","pubTimestamp":1792586820,"startTime":"0","endTime":"0","summary":"10月21日，腾盛博药生物科技有限公司(证券代号：02137)于2026年10月21日在香港联合交易所回购16000股普通股，每股回购价为HKD0.905，付出的价格总额为HKD14480。回购股份被持作库存股份，拟 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261021/c680946811.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261021/c680946811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677617330","title":"OpenAI宣布收购AI生物科技初创企业Orchestra Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2677617330","media":"IT之家","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677617330?lang=zh_cn&edition=full","pubTime":"2026-10-21 06:52","pubTimestamp":1792536726,"startTime":"0","endTime":"0","summary":"IT之家 10 月 21 日消息，OpenAI 于当地时间周二宣布，收购成立四年的人工智能生物科技软件初创企业 Orchestra Bio，相关消息由该公司在官网发布。Orchestra Bio 开发 AI 智能体，助力生物科技企业管理药物研发业务中的各类细碎工作，涵盖资金追踪，以及解决临床试验的排期问题。OpenAI 表示，将吸纳 Orchestra Bio 的团队与技术，投入 Rosalind 项目的研发。OpenAI 称，Rosalind 已经拿下多家知名企业客户，其中包括莫德纳和诺和诺德。而这一次，Orchestra Bio 是被收购整合，而非遭到碾压淘汰。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8xOYA1sibTy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["XBI","CHAT","AGNG","IBBJ","MEDX","SYNB","BK4581","LNGR","QTOC","ARTY","AGIX","BK4585","VTHR","159837","IEIH","GDOC","AIPO","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676714691","title":"腾盛博药生物科技回购3万股 涉资约2.67万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2676714691","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676714691?lang=zh_cn&edition=full","pubTime":"2026-10-20 22:07","pubTimestamp":1792505220,"startTime":"0","endTime":"0","summary":"腾盛博药生物科技有限公司于2026年10月20日在香港联交所回购30000股普通股，每股最高回购价HKD0.89，最低回购价HKD0.885，付出价格总额HKD26617.5。回购股份持作库存股份，拟注销数目为0。 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261020/c680900970.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261020/c680900970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159837"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794512801912,"stockEarnings":[{"period":"1week","weight":-0.0358},{"period":"1month","weight":-0.0082},{"period":"3month","weight":-0.0744},{"period":"6month","weight":0.0275},{"period":"1year","weight":-0.0883},{"period":"ytd","weight":-0.0182}],"compareEarnings":[{"period":"1week","weight":-0.0092},{"period":"1month","weight":-0.0382},{"period":"3month","weight":-0.0691},{"period":"6month","weight":-0.116},{"period":"1year","weight":-0.0861},{"period":"ytd","weight":-0.0789}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(159837)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(159837)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,159837,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(159837)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(159837)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}